FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer
Evidence for efficacy is based on the results from the CodeBreaK 300 study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Evidence for efficacy is based on the results from the CodeBreaK 300 study
Findings from the CheckMate 7FL and KEYNOTE-756 studies
Findings from a final analysis of the JAVELIN Renal 101 study
Findings from the ESOPEC study
Evidence for efficacy is based on the results from the CHECKMATE-67T study
Evidence for efficacy is based on the results from the eXALT3 study
Findings from the CheckMate 8HW study
Findings from a randomised, controlled study
Findings from a model-based study using population-level data
Evidence for efficacy is based on the results from the Study CK-301-101
New indication concerns monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor ALL
Findings from the SGNTUC-019 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.